Abstract:
A tissue ablation device (10) has a handle (12) and an ablation head (14) coupled to the handle. The ablation head has a first jaw (24), a second jaw, and an ablative element (28) coupled to at least one of the first and second jaws. A thickness measurement device (40) may be coupled to the ablation device to indicate the distance separating the first and second jaws. Further, a force measurement device (50) may be coupled to the ablation device to measure the force being applied by the first and second jaws to a piece of tissue. Further, a strain measurement device (60) may be coupled to the ablation device to indicate the strain resulting in a piece of tissue disposed between the first and second jaws when a stress is applied to the tissue.
Abstract:
An implantable medical device system and method are provided for synchronizing atrial cardioversion shocks to the ventricular rhythm using an adjustable atrial cardioversion/defibrillation ventricular refractory period. Upon determining a need for an atrial shock therapy, the method determines if the ventricular rate meets synchronization criteria based on an upper ventricular refractory period limit. If synchronization criteria are not met, the refractory period is automatically adjusted in stepwise decrements until the synchronization criteria are met, or until a lower refractory period limit is exceeded. If synchronization criteria are met, an atrial shock is synchronized to the next ventricular depolarization occurring outside the current refractory period. If the lower refractory period limit is exceeded, the atrial therapy is aborted.
Abstract:
AbstractThe invention relates to the use of atrial pacing therapies to treat atrial tachycardia (AT). When an AT episode is detected, an implantable medical device applies an ATP therapy. If the AT episode persists, the ATP therapy may be automatically reapplied at a later time during the course of the same AT episode. In particular, previously used ATP therapies are reapplied when episodic conditions, such as cycle length or cycle regularity, change. Although a particular ATP therapy initially may be unsuccessful in terminating the AT, it may prove successful when the cycle length or regularity of the atrial rhythm changes. As the rhythm slows down, the AT may be more responsive to ATP therapies that were previously unsuccessful. As a result, potentially efficacious ATP therapies can be reapplied to terminate AT episodes, and reduce the number of episodes that require more aggressive termination by painful, atrial shocks.
Abstract:
An implantable cardioverter including two electrodes for sensing depolarizations of a chamber of a patient's heart one, electrode providing a near field signal, one electrode providing a far field signal. The device defines a desired cardioversion pulse delivery time as a first time interval following the onset of the far field signal. The device measures a second time interval between the onset of the far field signal and the detection of the near field signal, and delivers the cardioversion pulse synchronized to the detection of the near field signal, using the first and second time intervals to define a synchronization interval following detection of the near field electrogram.
Abstract:
AbstractThe invention relates to the use of atrial pacing therapies to treat atrial tachycardia (AT). When an AT episode is detected, an implantable medical device applies an ATP therapy. If the AT episode persists, the ATP therapy may be automatically reapplied at a later time during the course of the same AT episode. In particular, previously used ATP therapies are reapplied when episodic conditions, such as cycle length or cycle regularity, change. Although a particular ATP therapy initially may be unsuccessful in terminating the AT, it may prove successful when the cycle length or regularity of the atrial rhythm changes. As the rhythm slows down, the AT may be more responsive to ATP therapies that were previously unsuccessful. As a result, potentially efficacious ATP therapies can be reapplied to terminate AT episodes, and reduce the number of episodes that require more aggressive termination by painful, atrial shocks.
Abstract:
A patient-controlled system for temporarily disabling an electrical cardioverting therapy in order to prepare the patient psychologically and physiologically for the pain associated with electrical cardioversion therapy. In an example embodiment, the system includes a capacitive circuit capable of charging and discharging in order to apply the electrical therapy. The implanted medical device automatically causes the capacitive circuit to charge and discharge at least once within a selected period. The system includes a patient activator device that communicates with the implanted device. A disabling circuit is also included within the implanted medical device that temporarily disables the electrical therapy application in response to the patient activator device. The system further includes an alerting arrangement that alerts the patient activator device in response to the disabling circuit. An override circuit overrides the temporary disabling of the electrical therapy application in response to the patient being in a relaxed mode.
Abstract:
Notifying a patient or another person of an arrhythmia episode facilitates management of atrial fibrillation (AF) and other arrhythmias, including atrial flutter, atrial tachycardia, and supra ventricular tachycardia, thus enabling the patient to take corrective action even in the absence of symptoms or latent cardiac problems. For example, the patient may be prompted to take a medication, to initiate electrical therapy in the form of pacing or defibrillation, or to seek medical attention. Notification may be issued either by an implantable medical device (12) or by an external device (58) in communication with the implantable medical device (12). Various types of notifications may be issued under a variety of conditions, some of which may be associated with the duration of an episode.
Abstract:
A stimulator for applying stimulus pulses to the AV nodal fat pad in response to sensed atrial rate exceeding a predetermined rate, in order to reduce the ventricular rate. The device also includes a cardiac pacemaker which serves to pace the ventricle in the event that the ventricular rate is lowered below a pacing rate, and provides for feedback control of the stimulus parameters applied to the AV nodal fat pad, as a function of the determined effect of the stimulus pulses on the ventricular rate.
Abstract:
An implantable transvenous defibrillation/cardioversion lead. The lead extends from a proximal end carrying electrical connectors to a bifurcated distal end. Distal to the bifurcation are a first, generally straight leg (11) and a second, curved leg (13). In use, the distal end of the first, generally straight leg is located in the apex of the right ventricle and the distal end of the second generally curved leg is located in the outflow tract from the right ventricle, with the point of bifurcation located approximately adjacent the tricuspid valve. Elongated coil electrodes (30, 32) are provided extending along the straight and curved legs, distal to the point of bifurcation of lead. The lead may be used in conjunction with a subcutaneous or other additional defibrillation/cardioversion electrode.
Abstract:
A medical delivery system for delivering a fluid to a desired location within a body that includes a first member (204) having an aperture (206), and a second member (202) adapted to be positioned over the first member. The fluid to be delivered is contained within a fluid storage device (209), formed by at least one of the first member and the second member. The medical delivery system includes means (214, 222) made from shape memory allay for repositioning the first member relative to the second member between a first state preventing passage of the fluid through the aperture and a second state enabling passage of the fluid outward from the fluid storage device through the aperture, thus to form a kind of shutter or slide valve.